Liquisolid systems are an innovative dosage form used for enhancing dissolution rate and improving in vivo bioavailability of poorly soluble drugs. These formulations require specific evaluation methods for their quality assurance (e.g., evaluation of angle of slide, contact angle, or water absorption ratio). The presented study is focused on the preparation, modern in vitro testing, and evaluation of differences of liquisolid systems containing varying amounts of a drug in liquid state (polyethylene glycol 400 solution of rosuvastatin) in relation to an aluminometasilicate carrier (Neusilin US2). Liquisolid powders used for the formulation of final tablets were prepared using two different methods: simple blending and spraying of drug solution onto a carrier in fluid bed equipment. The obtained results imply that the amount of liquid phase in relation to carrier material had an effect on the hardness, friability, and disintegration of tablets, as well as their height. The use of spraying technique enhanced flow properties of the prepared mixtures, increased hardness values, decreased friability, and improved homogeneity of the final dosage form.

Department of Pharmaceutics Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Palackého 1 3 612 42 Brno Czech Republic

Zobrazit více v PubMed

Savjani K. T., Gajjar A. K., Savjani J. K. Drug solubility: importance and enhancement techniques. ISRN Pharmaceutics. 2012;2012:10. doi: 10.5402/2012/195727.195727 PubMed DOI PMC

Hiendrawan S., Veriansyah B., Tjandrawinata R. R. Micronization of fenofibrate by rapid expansion of supercritical solution. Journal of Industrial and Engineering Chemistry. 2014;20(1):54–60. doi: 10.1016/j.jiec.2013.04.027. DOI

Nighute A. B., Bhise S. B. Enhancement of dissolution rate of rifabutin by preparation of microcrystals using solvent change method. International Journal of PharmTech Research. 2009;1(2):142–148.

Burra M., Jukanti R., Janga K. Y., et al. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Advanced Powder Technology. 2013;24(1):393–402. doi: 10.1016/j.apt.2012.09.002. DOI

Qi X., Qin J., Ma N., Chou X., Wu Z. Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation. International Journal of Pharmaceutics. 2014;472(1-2):40–47. doi: 10.1016/j.ijpharm.2014.06.019. PubMed DOI

Kavitha K., Lova Raju K. N. S., Ganesh N. S., Ramesh B. Effect of dissolution rate by liquisolid compact approach: an overview. Der Pharmacia Lettre. 2011;3(1):71–83.

Nagabandi V. K., Ramarao T., Jayaveera K. N. Liquisolid compacts: a novel approach to enhance bioavailability of poorly soluble drugs. International Journal of Pharma and Bio Sciences. 2011;1:89–102.

Gubbi S. R., Jarag R. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian Journal of Pharmaceutical Sciences. 2010;5(2):50–60.

Javadzadeh Y., Jafari-Navimipour B., Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine) International Journal of Pharmaceutics. 2007;341(1-2):26–34. doi: 10.1016/j.ijpharm.2007.03.034. PubMed DOI

Akinlade B., Elkordy A. A., Essa E. A., Elhagar S. Liquisolid systems to improve the dissolution of Furosemide. Scientia Pharmaceutica. 2010;78(2):325–344. doi: 10.3797/scipharm.0912-23. PubMed DOI PMC

Saeedi M., Akbari J., Morteza-Semnani K., Enayati-Fard R., Sar-Reshteh-dar S., Soleymani A. Enhancement of dissolution rate of indomethacin using liquisolid compacts. Iranian Journal of Pharmaceutical Research. 2011;10(1):25–34. PubMed PMC

Nokhodchi A., Hentzschel C. M., Leopold C. S. Drug release from liquisolid systems: speed it up, slow it down. Expert Opinion on Drug Delivery. 2011;8(2):191–205. doi: 10.1517/17425247.2011.548801. PubMed DOI

Fahmy R. H., Kassem M. A. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics. 2008;69(3):993–1003. doi: 10.1016/j.ejpb.2008.02.017. PubMed DOI

Gavali S. M., Pacharane S. S., Sankpal S. V., Jadhav K. R., Kadam V. J. Liquisolid compact: a new technique for enhancement of drug dissolution. International Journal of Research in Pharmacy and Chemistry. 2011;1:2231–2781.

Yadav V. B., Yadav A. V. Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique. Journal of Pharmaceutical Sciences and Research. 2009;1(3):44–51.

Karmarkar A. B., Gonjari I. D., Hosmani A. H. Liquisolid technology for dissolution rate enhancement or sustained release. Expert Opinion on Drug Delivery. 2010;7(10):1227–1234. doi: 10.1517/17425247.2010.511173. PubMed DOI

Tiong N., Elkordy A. A. Effects of liquisolid formulations on dissolution of naproxen. European Journal of Pharmaceutics and Biopharmaceutics. 2009;73(3):373–384. doi: 10.1016/j.ejpb.2009.08.002. PubMed DOI

Kaur M., Bala R., Arora S. Formulation and evaluation of liquisolid compacts of amlodipine besylate. International Research Journal of Pharma. 2013;4:156–160.

Jones P. H., Davidson M. H., Goldberg A. C., et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology. 2009;3(2):125–137. doi: 10.1016/j.jacl.2009.02.007. PubMed DOI

Toth P. P., Zarotsky V., Sullivan J. M., Laitinen D. Lipid therapy utilization rates in a managed-care mixed dyslipidemia population. Journal of Clinical Lipidology. 2008;2(5):365–374. doi: 10.1016/j.jacl.2008.08.443. PubMed DOI

Anfossi G., Massucco P., Bonomo K., Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutrition, Metabolism and Cardiovascular Diseases. 2004;14(4):215–224. doi: 10.1016/S0939-4753(04)80008-5. PubMed DOI

McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis Supplements. 2003;4(1):9–14. doi: 10.1016/S1567-5688(03)00004-7. PubMed DOI

Chapman M. J., McTaggart F. Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atherosclerosis Supplements. 2002;2(4):33–37. doi: 10.1016/S1567-5688(01)00016-2. PubMed DOI

Martin P. D., Warwick M. J., Dane A. L., et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clinical Therapeutics. 2003;25(11):2822–2835. doi: 10.1016/S0149-2918(03)80336-3. PubMed DOI

Spireas S., Bolton S. M. Liquisolid systems and methods of preparing same. US6423339; 2002.

Spireas S., Bolton S. M. Liquisolid systems and methods of preparing same. 2000;(US8096337)

Vraníková B., Gajdziok J., Vetchý D. Determination of flowable liquid retention potential of aluminometasilicate carrier for liquisolid systems preparation. Pharmaceutical Development and Technology. 2014 doi: 10.3109/10837450.2014.926921. PubMed DOI

The European Directorate for the Quality of Medicines & HealthCare: European Pharmacopoeia 8.2. 2014, http://online6.edqm.eu/ep802.

Karmarkar A. B., Gonjari I. D., Hosmani A. H., Dhabale P. N., Bhise S. B. Liquisolid tablets: a novel approach for drug delivery. International Journal of Health Research. 2009;2(1):45–50. doi: 10.4314/ijhr.v2i1.55386. DOI

Spireas S. S., Jarowski C. I., Rohera B. D. Powdered solution technology: principles and mechanism. Pharmaceutical Research. 1992;9(10):1351–1358. doi: 10.1023/A:1015877905988. PubMed DOI

Gumaste S. G., Pawlak S. A., Dalrymple D. M., Nider C. J., Trombetta L. D., Serajuddin A. T. M. Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on tableting properties and surface structures of different silicates. Pharmaceutical Research. 2013;30(12):3170–3185. doi: 10.1007/s11095-013-1114-4. PubMed DOI PMC

Hentzschel C. M., Sakmann A., Leopold C. S. Suitability of various excipients as carrier and coating materials for liquisolid compacts. Drug Development and Industrial Pharmacy. 2011;37(10):1200–1207. doi: 10.3109/03639045.2011.564184. PubMed DOI

DMV Excipient Guide. [Internet] 2014, http://www.phexcom.cn/UploadFiles/20130217102234_5017.pdf.

Poutiainen S., Matero S., Hämäläinen T., Leskinen J., Ketolainen J., Järvinen K. Predicting granule size distribution of a fluidized bed spray granulation process by regime based PLS modeling of acoustic emission data. Powder Technology. 2012;228:149–157. doi: 10.1016/j.powtec.2012.05.010. DOI

Hentzschel C. M., Alnaief M., Smirnova I., Sakmann A., Leopold C. S. Enhancement of griseofulvin release from liquisolid compacts. European Journal of Pharmaceutics and Biopharmaceutics. 2012;80(1):130–135. doi: 10.1016/j.ejpb.2011.08.001. PubMed DOI

Prajapati S. T., Bulchandani H. H., Patel D. M., Dumaniya S. K., Patel C. N. Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. Journal of Drug Delivery. 2013;2013:9. doi: 10.1155/2013/870579.870579 PubMed DOI PMC

Komárek P., Rabišková M. Technologie léků Třetí, přepracované a doplněné vydání. Praha, Czech Republic: Galén; 2006.

Gumaste S. G., Dalrymple D. M., Serajuddin A. T. M. Development of solid SEDDS, V: compaction and drug release properties of tablets prepared by adsorbing lipid-based formulations onto neusilin US2. Pharmaceutical Research. 2013;30(12):3186–3199. doi: 10.1007/s11095-013-1106-4. PubMed DOI PMC

Elkordy A. A., Tan X. N., Essa E. A. Spironolactone release from liquisolid formulations prepared with Capryol 90, Solutol HS-15 and Kollicoat SR 30 D as non-volatile liquid vehicles. European Journal of Pharmaceutics and Biopharmaceutics. 2013;83(2):203–223. doi: 10.1016/j.ejpb.2012.08.004. PubMed DOI

Gubbi S., Jarag R. Liquisolid technique for enhancement of dissolution properties of bromhexine hydrochloride. Research Journal of Pharmacy and Technology. 2009;2(2):382–386.

Kapure V. J., Pande V. V., Deshmukh P. K. Dissolution enhancement of rosuvastatin calcium by liquisolid compact technique. Journal of Pharmaceutics. 2013;2013:9. doi: 10.1155/2013/315902.315902 PubMed DOI PMC

Saigal N., Baboota S., Ahuja A., Ali J. Microcrystalline cellulose as a versatile excipient in drug research. Journal of Young Pharmacists. 2009;1:6–12. doi: 10.4103/0975-1483.51868. DOI

Sanka K., Poienti S., Mohd A. B., Diwan P. V. Improved oral delivery of clonazepam through liquisolid powder compact formulations: in-vitro and ex-vivo characterization. Powder Technology. 2014;256:336–344. doi: 10.1016/j.powtec.2014.02.026. DOI

Sayyad F. J., Tulsankar S. L., Kolap U. B. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. Journal of Pharmacy Research. 2013;7(5):381–388. doi: 10.1016/j.jopr.2013.05.012. DOI

Comparative Study of Powder Carriers Physical and Structural Properties

Technology of Processing Plant Extracts Using an Aluminometasilicate Porous Carrier into a Solid Dosage Form

Comparison of Flow and Compression Properties of Four Lactose-Based Co-Processed Excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®

Evaluation and Comparison of Three Types of Spray Dried Coprocessed Excipient Avicel® for Direct Compression